Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 68.85B 60.16B 55.52B 51.17B 96.45B 6,630B 98.59B 664B 261B 3,247B 259B 253B 11,178B P/E 2026 *
17.8x
P/E 2027 * 14.3x
Enterprise Value 61.02B 53.33B 49.21B 45.36B 85.49B 5,877B 87.39B 588B 231B 2,878B 229B 224B 9,908B EV / Sales 2026 *
3.85x
EV / Sales 2027 * 3.31x
Free-Float
72.33%
Yield 2026 *
0.58%
Yield 2027 * 0.66%
1 day-0.33%
1 week+1.83%
Current month+8.52%
1 month+10.94%
3 months-9.84%
6 months-7.69%
Current year-12.33%
1 week 648.66
Extreme 648.66
691.13
1 month 594.9
Extreme 594.9
691.13
Current year 591.52
Extreme 591.52
821.11
1 year 541
Extreme 541
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap.
2/7/26 Sell

Director

-200 0.0002%
1/5/26 Sell

Director

-100 0.0001%
1/4/26 Sell

Director

100 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.33%+1.83%+24.73%-6.86% 68.85B
+0.67%+0.93%+36.86%+197.49% 52.13B
+0.94%+39.60%+39.60%+39.60% 43.46B
+1.12%+0.35%-52.09%-53.39% 41.24B
-1.40%+3.43%+64.81%-25.41% 30.41B
-2.11%-9.45%+97.76%-49.58% 24.53B
+0.51%+0.46%+72.78%+90.09% 23.42B
-5.57%-0.84%-0.11%+182.38% 19.75B
-0.86%-1.99%+70.03%+117.01% 16.57B
+1.34%-5.25%+74.97%+150.25% 15.95B
Average -0.57%-1.25%+42.93%+64.16% 33.63B
Weighted average by Cap. -0.26%-0.31%+34.57%+51.74%

Financials

2026 *2027 *
Net sales 15.86B 13.86B 12.79B 11.79B 22.22B 1,527B 22.71B 153B 60.13B 748B 59.56B 58.25B 2,575B 17.64B 15.42B 14.23B 13.12B 24.72B 1,699B 25.27B 170B 66.89B 832B 66.26B 64.81B 2,865B
Net income 3.99B 3.49B 3.22B 2.97B 5.59B 384B 5.71B 38.45B 15.12B 188B 14.98B 14.65B 648B 5.03B 4.39B 4.05B 3.74B 7.04B 484B 7.2B 48.45B 19.05B 237B 18.88B 18.46B 816B
Net Debt -7.82B -6.84B -6.31B -5.81B -10.96B -753B -11.2B -75.4B -29.66B -369B -29.38B -28.73B -1,270B -10.51B -9.19B -8.48B -7.81B -14.73B -1,012B -15.06B -101B -39.86B -496B -39.48B -38.62B -1,707B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
17/07/26 USD 676.69 -0.33% 648,400
16/07/26 USD 678.94 +2.18% 730,245
15/07/26 USD 664.45 +1.27% 555,419
14/07/26 USD 656.12 -1.05% 477,991
13/07/26 USD 663.09 -0.22% 606,304
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
676.69USD
Average target price
819.18USD
Spread / Average Target
+21.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock